Children (the plural of child) are young humans before they reach adulthood, or the offspring of an adult of any species.

Children may also refer to''':

• Children (song) a dreamhouse musical single by Robert Miles
• 3, a ska band
• Children (play), a play by A. R. Gurney

More on [ Children (disambiguation) ]

All Ophthalmology Jobs

Permanent Ophthalmology Job in Williamsport Pennsylvania with Susquehanna Health
Susquehanna Health is seeking an Ophthalmologist to join one (1) other in our practice and two (2) others that are in private practice here in Williamsport, Pennsylvania. Be part of the team that is
Permanent Ophthalmology Job in Not Disclosed Nevada with Locum Medical Group
The VA is in need of an Ophthalmologist for their facility in Reno, Nevada. The assignment will begin in September and will continue for three months. A NV medical license is not required for this opportunity.
Permanent Ophthalmology Job in AL statewide Alabama with Medical Doctor Associates, Inc.
Outstanding opportunity for BC/BE Ophthalmologist to join existing practice. Tremendous growth within the community requires recruitment. Excellent financial package with Sign On Bonus. Located in

Current Opinion in Ophthalmology - Current Table Of Contents

Editorial introductions.
Page: viDOI: 10.1097/ICU.0b013e328311f053
Pediatric strabismus imaging.
Page: 371DOI: 10.1097/ICU.0b013e328309f165Authors: Kadom, Nadja
Recent developments in the field of superior oblique palsies.
Page: 379DOI: 10.1097/ICU.0b013e328309f191Authors: Madigan, William P; Zein, Wadih M

Archives of Ophthalmology current issue

ABOUT THIS JOURNAL: About This Journal
Mon, 08 Sep 2008 00:00:00 -0000

CLINICAL TRIAL: Treatment of Posterior Uveitis With a Fluocinolone Acetonide Implant: Three-Year Clinical Trial Results
Callanan, D. G., Jaffe, G. J., Martin, D. F., Pearson, P. A., Comstock, T. L. Mon, 08 Sep 2008 00:00:00 -0000
Objectives  To evaluate the safety and efficacy of 0.59-mg and 2.1-mg fluocinolone acetonide (FA) intravitreous implants in noninfectious posterior uveitis. Design  A 3-year, multicenter, randomized, historically controlled trial of the 0.59-mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients. Main Outcome Measures  Recurrence rate, vision, and complications. Results  Uveitis recurrence was reduced in implanted eyes from 62% (during the 1-year preimplantation period) to 4%, 10%, and 20% during the 1-, 2-, and 3-year postimplantation periods, respectively, for the 0.59-mg dose group (P < .01) and from 58% to 7%, 17%, and 41%, respectively, for the 2.1-mg dose group (P < .01). More implanted eyes than nonimplanted eyes had improved visual acuity (P < .01). Implanted eyes had higher incidences of intraocular pressure elevation (≥ 10 mm Hg) than nonimplanted eyes (P < .01), and glaucoma surgery was required in 40% of implanted eyes vs 2% of nonimplanted eyes (P < .01). Cataracts were extracted in 93% of phakic implanted eyes vs 20% of phakic nonimplanted eyes (P < .01). Conclusions  The FA implant significantly reduced uveitis recurrence and improved or stabilized visual acuity in subjects with noninfectious posterior uveitis. Most subjects required cataract extraction, and a significant proportion required intraocular pressure–lowering surgery. Application to Clinical Practice  The FA implant provides an alternative therapy for prolonged control of inflammation in noninfectious posterior uveitis. Trial Registration  clinicaltrials.gov Identifier: NCT00407082
CLINICAL TRIAL: Topical Ketorolac in Vitreoretinal Surgery: A Prospective, Randomized, Placebo-Controlled, Double-Masked Trial
Kim, S. J., Lo, W. R., Hubbard, G. B., Srivastava, S. K., Denny, J. P., Martin, D. F., Yan, J., Bergstrom, C. S., Cribbs, B. E., Schwent, B. J., Aaberg, T. M. Mon, 08 Sep 2008 00:00:00 -0000
Objective  To evaluate the effects of topical ketorolac in patients undergoing vitreoretinal surgery. Methods  One hundred nine patients undergoing vitrectomies were randomized to receive either topical ketorolac tromethamine, 0.4%, or placebo. Patients were instructed to begin taking the study medication 3 days preoperatively (4 times daily) and to continue taking it 4 weeks postoperatively. Main Outcome Measures  Intraoperative pupil diameter, postoperative day 1 pain and inflammation, 1-month postoperative retinal thickness, and preoperative and 1-month postoperative best-corrected visual acuities. Results  The difference in mean pupil diameters between patients using ketorolac and those taking placebo was 0.06 mm (P = .39). Patients taking ketorolac and those taking placebo had mean pain scores (scale, 1-10) of 0.24 (SD, 0.6) and 1.06 (SD, 2) (P = .03) and mean inflammation grades (grade, 0-4) of 0.59 (SD, 0.7) and 1.16 (SD, 0.9) (P < .001), respectively. Ketorolac reduced central subfield thickness by 8%, but this was not statistically significant. At 1 month, mean visual acuities improved to 0.40 logMAR units (mean Snellen, 20/50; SD, 0.28 logMAR units) in the ketorolac group from 0.83 logMAR units (20/150+2; SD, 0.60 logMAR units) at baseline and to 0.67 logMAR units (20/100+1; SD, 0.46 logMAR units) in the placebo group from 0.92 logMAR units (20/150–2; SD, 0.62 logMAR units) at baseline (P = .001). Conclusions  Topical ketorolac was well tolerated and safe, reduced postoperative pain and inflammation, and improved visual recovery in this prospective, double-masked trial. Application to Clinical Practice  Topical ketorolac may benefit patients undergoing vitreoretinal surgery. Trial Registration  clinicaltrials.gov Identifier: NCT00576329

Subscribe to Ophthalmology RSS feed